迪安诊断 reported revenue of ¥4.77B for the period ended 2026-06-30, -3.3% year on year. Net income was ¥0.32B, a 6.7% net margin on a 30.1% gross margin. The largest revenue line is 渠道产品 at 65% of the total. Free cash flow for the period was ¥0.34B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥4.77B | -3.3% |
| Gross profit | ¥1.44B | — |
| Operating income | ¥0.45B | — |
| Net income | ¥0.32B | +290.2% |
| Gross margin | 30.1% | Net margin 6.7% |
| Revenue Q/Q | +12.4% | — |
| Segment | Revenue | Share |
|---|---|---|
| 渠道产品 | ¥3.08B | 64.5% |
| 诊断服务 | ¥1.66B | 34.8% |
| 其他主营业务 | ¥0.03B | 0.6% |
| 其他(补充) | ¥0.00B | 0.1% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥3.34B | 69.9% |
| R&D | ¥0.10B | 2.0% |
| SG&A | ¥0.79B | 16.5% |
| Tax & other | ¥0.13B | 2.6% |
| Item | Amount |
|---|---|
| Total assets | ¥13.84B |
| Total liabilities | ¥5.25B |
| Shareholders' equity | ¥8.58B |
| Equity / assets | 62.0% |
| Operating cash flow | ¥0.42B |
| Capital expenditure | ¥0.08B |
| Free cash flow | ¥0.34B |
| Cash conversion (OCF / net income) | 81% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
ST天玑 ・ 宝莱特 ・ 融捷健康 ・ 新开普 ・ 依米康 ・ 初灵信息 ・ 金信诺 ・ 卫宁健康 ・ 仟源医药 ・ 常山药业 ・ 星星科技 ・ 开山股份
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies